In vivo evaluation of Sono-chemo therapy via hollow gold nanoshells conjugated to mitoxantrone on breast cancer

Document Type : Original Article


1 Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran



Objective(s): Conventional methods of cancer treatment include surgery, chemotherapy, radiation therapy, and immunotherapy. Chemotherapy, as one of the main methods of cancer treatment, due to the lack of targeted distribution of the drug in tumor tissues, is not able to destroy cancer cells and also affects healthy tissues and causes serious side effects in patients. Sonodynamic therapy (SDT) is a promising strategy for non-invasive treatment of deep solid cancer tumors. In this study, for the first time, the sono-sensitive activity of mitoxantrone was investigated and then mitoxantrone (MTX) was conjugated to hollow gold nanostructure (HGN) to improve the efficiency of in vivo SDT. 
Materials and Methods: Firstly, after the synthesis of hollow gold nanoshells and the PEGylation process, conjugation of MTX was performed. Then, after evaluating the toxicity of the treatment groups in vitro, in order to perform an in vivo study, 56 male Balb/c mice that had been tumorized by subcutaneous injection of 4T1 cells were divided into eight groups of breast tumor model. Ultrasonic irradiation (US) conditions including intensity of 1.5 W/cm2 (with a frequency of 800 kHz, 5 min), MTX concentration of 2 μM, and HGN dose of 2.5 mg/kg (unit of animal weight) were used.
Results: The results show that administration of PEG-HGN-MTX caused a slight reduction in tumor size and growth compared with free MTX. Ultrasound also improved the therapeutic effect of the gold nanoshell in treated groups, and the HGN-PEG-MTX-US treated groups were able to significantly reduce and control tumor size and growth. 
Conclusion: The findings also show that MTX and HGN can be used as sonosensitizers in SDT. Also, HGN-PEG-MTX can act as a sono-chemotherapy agent for the combination of sonodynamic therapy and chemotherapy for in vivo breast tumors.


1. Canavese G, Ancona A, Racca L, Canta M, Dumontel B, Barbaresco F, et al. Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer. Chemical Engineering Journal. 2018;340:155-72.
2. Shibaguchi H, Tsuru H, Kuroki M, Kuroki M. Sonodynamic cancer therapy: A non-invasive and repeatable approach using low-intensity ultrasound with a sonosensitizer. Anticancer Res 2011;31:2425-2429.
3. Serpe L, Foglietta F, Canaparo R. Nanosonotechnology: The next challenge in cancer sonodynamic therapy. Nanotechnology Rev 2012;1:173-182.
4. Xu M, Zhou L, Zheng L, Zhou Q, Liu K, Mao Y, et al. Sonodynamic therapy-derived multimodal synergistic cancer therapy. Cancer Lett 2021;497:229-242.
5. Maloney E, Hwang JH. Emerging HIFU applications in cancer therapy. Int J Hyperthermia 2015;31:302-309.
6. Zhong X, Zhang M, Tian Z, Wang Q, Wang Z. The study of enhanced high-intensity focused ultrasound therapy by sonodynamic N2O microbubbles. Nanoscale Res Lett 2019;14:381.
7. Baker KG, Robertson VJ, Duck FA. A review of therapeutic ultrasound: biophysical effects. Phys ther 2001;81:1351-1358.
8. Chen H, Zhou X, Gao Y, Zheng B, Tang F, Huang J. Recent progress in development of new sonosensitizers for sonodynamic cancer therapy. Drug Discov Today 2014;19:502-509.
9. Son S, Kim JH, Wang X, Zhang C, Yoon SA, Shin J, et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev 2020;49:3244-3261.
10. Xu H, Zhang X, Han R, Yang P, Ma H, Song Y, et al. Nanoparticles in sonodynamic therapy: State of the art review. RSC adv 2016;6:50697-50705.
11. Douglas S, Davis S, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 1987;3:233-261.
12. Sperling RA, Gil PR, Zhang F, Zanella M, Parak WJ. Biological applications of gold nanoparticles. Chem Soc Rev 2008;37:1896-1908.
13. Jain S, Hirst D, O’Sullivan J. Gold nanoparticles as novel agents for cancer therapy. British J Radiol 2012;85:101-113.
14. Nyokong T, Antunes E. Influence of nanoparticle materials on the photophysical behavior of phthalocyanines. Coord Chem Rev 2013;257:2401-2418.
15. Yoon J-H, Cho H-J, Jin H-E, Maeng H-J. Mitoxantrone-loaded PEGylated gold nanocomplexes for cancer therapy. J Nanosci Nanotechnol 2019;19:687-690.
16. Imanparast A, Bakhshizadeh M, Salek R, Sazgarnia A. Pegylated hollow gold-mitoxantrone nanoparticles combining photodynamic therapy and chemotherapy of cancer cells. Photodiagnosis Photodyn Ther 2018;23:295-305.
17. Sazgarnia A, Montazerabadi AR, Bahreyni-Toosi MH, Ahmadi A. Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. Lasers Med Sci 2013;28:1533-1539.
18. Das R, Rinaldi-Montes N, Alonso J, Amghouz Z, Garaio E, Garcia JA, et al. Boosted hyperthermia therapy by combined AC magnetic and photothermal exposures in Ag/Fe3O4 nanoflowers. ACS Appl Mater Interfaces 2016;8:25162-25169.
19. Shanei A, Mirzaeiyan M, Hejazi H. Destructive effects of therapeutic ultrasound and gold nanoparticles on a breast carcinoma tumor model in BALB/c mice. Int J Radiation Res 2020;18:743-751.
20. Qin SY, Cheng YJ, Lei Q, Zhang AQ, Zhang XZ. Combinational strategy for high-performance cancer chemotherapy. Biomaterials 2018;171:178-197.
21. Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 2016;43:723-737.
22. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010;46:308-316.
23. Wang J, Seebacher N, Shi H, Kan Q, Duan Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 2017;8:84559-84571.
24. Turajlic S, Swanton C. Implications of cancer evolution for drug development. Nat Rev Drug Discov 2017;16:441-442.
25. Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget 2017;8:3933-3945.
26. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 2005;4:255-260.
27. Irajirad R, Ahmadi A, Najafabad BK, Abed Z, Sheervalilou R, Khoei S, et al. Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study. Cancer Chemother Pharmacol 2019;84:1315-1321.
28. Zhang X, Teodoro JG, Nadeau JL. Intratumoral gold-doxorubicin is effective in treating melanoma in mice. Nanomedicine 2015;11:1365-1375.
29. Sazgarnia A, Shanei A, Taheri AR, Meibodi NT, Eshghi H, Attaran N, et al. Therapeutic effects of acoustic cavitation in the presence of gold nanoparticles on a colon tumor model. J Ultrasound Med 2013;32:475-483.